R+D+i
Grifols research and development team works to create new products and innovative solutions for healthcare.
In the Bioscience area
There are two essential aspects to the R+D activity:
-
Industrial developments aimed at achieving new production methods that increase efficiency while guaranteeing the safety and quality standards in the plasma derivatives manufacturing process.
-
Research for obtaining new therapies and solutions for those people who suffer from illnesses stemming from plasma protein deficits, or from other pathologies where plasma therapies may be beneficial.
In the Diagnostic area
The Diagnostic area focuses on developing automatic analyzers and their corresponding highly sensitive reagents for obtaining reliable results, so that clinical laboratories can achieve optimum management of all tasks and higher productivity.Development of these analyzers is fuelled by the company’s experience and knowledge in areas such as biology, analytical chemistry, artificial vision, mechanical electronics and software engineering applied to analytics tests and to reading results.
In the Hospital area
The priority is to satisfy any needs that the hospital may have for pharmaceutical products and clinical nutrition. One of the lines of research involves developing electrolytic solutions and ready-to-use pharmaceutical preparations.
Given the importance that clinical nutrition has on patient recovery, Grifols develops complete diets for different patient nutritional requirements. In hospital logistics, innovation in the technological platforms is centered on automating the hospital supply warehouses and the equipment used for controlling how medicines are dispensed.
Pharmaceutical Engineering
Grifols Engineering provides innovative design to the pharmaceutical technology in our manufacturing plants. The know-how that has been acquired in the development of complex production processes, machinery and manufacturing installations means that Grifols is in an excellent position to offer engineering and consultancy services to other companies in the pharmaceutical and biotechnology industries.
| 